Competitive inhibition of renal tubular secretion of gemifloxacin by probenecid.
Probenecid interacts with transport processes of drugs at several sites in the body. For most quinolones, renal clearance is reduced by concomitant administration of probenecid. The interaction between gemifloxacin and probenecid has not yet been studied. We studied the extent, time course, site(s), and mechanism of this interaction. Seventeen healthy volunteers participated in a randomized, two-way crossover study. Subjects received 320 mg gemifloxacin as an oral tablet without and with 4.5 g probenecid divided in eight oral doses. Drug concentrations in plasma and urine were analyzed by liquid chromatography-tandem mass spectrometry. WinNonlin was used for noncompartmental analysis, compartmental modeling, and statistics, and NONMEM was used for visual predictive checks. Concomitant administration of probenecid increased plasma gemifloxacin concentrations and amounts excreted in urine compared to baseline amounts. Data are average estimates (percent coefficients of variation). Modeling showed a competitive inhibition of the renal tubular secretion of gemifloxacin by probenecid as the most likely mechanism of the interaction. The estimated K(m) and Vmax for the saturable part of renal elimination were 9.16 mg/liter (20%) and 113 mg/h (21%), respectively. Based on the molar ratio, the affinity for the renal transporter was 10-fold higher for gemifloxacin than for probenecid. Since probenecid reached an approximately 200-times-higher area under the molar concentration-time curve from 0 to 24 h than gemifloxacin, probenecid inhibited the active tubular secretion of gemifloxacin. Probenecid also reduced the nonrenal clearance of gemifloxacin from 25.2 (26%) to 21.0 (23%) liters/h. Probenecid inhibited the renal tubular secretion of gemifloxacin, most likely by a competitive mechanism, and slightly decreased nonrenal clearance of gemifloxacin.
Landersdorfer
Cornelia B
CB
IBMP-Institute for Biomedical and Pharmaceutical Research, Nürnberg-Heroldsberg, Germany.
Kirkpatrick
Carl M J
CM
Kinzig
Martina
M
Bulitta
Jürgen B
JB
Holzgrabe
Ulrike
U
Drusano
George L
GL
Sörgel
Fritz
F
D000277:Adjuvants, Pharmaceutic / Q000494:pharmacology*; D005260:Female; D024841:Fluoroquinolones / Q000097:blood* / Q000493:pharmacokinetics / Q000652:urine*; D000077735:Gemifloxacin; D006801:Humans; D007677:Kidney Function Tests; D007684:Kidney Tubules / Q000187:drug effects* / Q000378:metabolism*; D008297:Male; D008657:Metabolic Clearance Rate / Q000187:drug effects; D009287:Naphthyridines / Q000097:blood* / Q000493:pharmacokinetics / Q000652:urine*; D011339:Probenecid / Q000097:blood / Q000494:pharmacology* / Q000652:urine
D000277:Adjuvants, Pharmaceutic; D024841:Fluoroquinolones; D009287:Naphthyridines; D000077735:Gemifloxacin; D011339:Probenecid